Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 486386, 9 pages
http://dx.doi.org/10.1155/2014/486386
Research Article

Identification of Chemokines and Growth Factors in Proliferative Diabetic Retinopathy Vitreous

Department of Ophthalmology, Wuxi No. 2 Hospital, Nanjing Medical University, Zhongshan 68, Wuxi 214002, China

Received 8 July 2014; Revised 28 August 2014; Accepted 28 August 2014; Published 27 October 2014

Academic Editor: Maurizio Battaglia Parodi

Copyright © 2014 Ying Dai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. Abu El-Asrar, S. Struyf, D. Kangave, K. Geboes, and J. van Damme, “Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy,” European Cytokine Network, vol. 17, no. 3, pp. 155–165, 2006. View at Google Scholar · View at Scopus
  2. J. L. Bromberg-White, L. Glazer, R. Downer, K. Furge, E. Boguslawski, and N. S. Duesbery, “Identification of VEGF-independent cytokines in proliferative diabetic retinopathy vitreous,” Investigative Ophthalmology & Visual Science, vol. 54, no. 10, pp. 6472–6480, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Hirase, T. Ikeda, C. Sotozono, K. Nishida, H. Sawa, and S. Kinoshita, “Transforming growth factor β2 in the vitreous in proliferative diabetic retinopathy,” Archives of Ophthalmology, vol. 116, no. 6, pp. 738–741, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Murugeswari, D. Shukla, A. Rajendran, R. Kim, P. Namperumalsamy, and V. Muthukkaruppan, “Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales’ disease,” Retina, vol. 28, no. 6, pp. 817–824, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. G. P. Giuliari, “Diabetic retinopathy: current and new treatment options,” Current Diabetes Reviews, vol. 8, no. 1, pp. 32–41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. U. Chakravarthy, A. P. Adamis, E. T. Cunningham Jr. et al., “Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, pp. 1508.e1–1508.e25, 2006. View at Google Scholar
  7. O. Laplace, “Surgical session: neovascular glaucoma and anti-vascular endothelial growth factor treatment,” Journal Francais d'Ophtalmologie, vol. 32, no. 3, pp. 230–235, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Kang, C. R. Roh, W.-K. Cho et al., “Antiangiogenic effects of axitinib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on laser-induced choroidal neovascularization in mice,” Current Eye Research, vol. 38, no. 1, pp. 119–127, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. R. L. Avery, J. Pearlman, D. J. Pieramici et al., “Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy,” Ophthalmology, vol. 113, no. 10, pp. 1695.e1–1695.e15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Mirshahi, R. Roohipoor, A. Lashay, S.-F. Mohammadi, A. Abdoallahi, and H. Faghihi, “Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial,” European Journal of Ophthalmology, vol. 18, no. 2, pp. 263–269, 2008. View at Google Scholar · View at Scopus
  11. R. Simó and C. Hernández, “Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy,” Diabetologia, vol. 51, no. 9, pp. 1574–1580, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Casini, M. Dal Monte, I. Fornaciari, L. Filippi, and P. Bagnoli, “The β-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases,” Progress in Retinal and Eye Research, vol. 42C, pp. 103–129, 2014. View at Publisher · View at Google Scholar
  13. F. Semeraro, F. Morescalchi, S. Duse, E. Gambicorti, M. R. Romano, and C. Costagliola, “Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview,” Expert Opinion on Drug Safety, vol. 13, no. 6, pp. 785–802, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Wang, E. S. Wittchen, Y. Jiang, B. Ambati, H. E. Grossniklaus, and M. Elizabeth Hartnett, “Upregulation of CCR3 by age-related stresses promotes choroidal endothelial cell migration via VEGF-dependent and -independent signaling,” Investigative Ophthalmology and Visual Science, vol. 52, no. 11, pp. 8271–8277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Banerjee, V. Savant, R. A. H. Scott, S. J. Curnow, G. R. Wallace, and P. L. Murray, “Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders,” Investigative Ophthalmology and Visual Science, vol. 48, no. 5, pp. 2203–2207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Salcedo, H. A. Young, M. L. Ponce et al., “Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells,” The Journal of Immunology, vol. 166, no. 12, pp. 7571–7578, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Yoshimura, K.-H. Sonoda, M. Sugahara et al., “Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases,” PLoS ONE, vol. 4, no. 12, Article ID e8158, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Loukovaara, A. Robciuc, J. M. Holopainen et al., “Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFβ1 in diabetic eyes undergoing vitrectomy,” Acta Ophthalmologica, vol. 91, no. 6, pp. 531–539, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. M. I. Nawaz, K. van Raemdonck, G. Mohammad et al., “Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy,” Experimental Eye Research, vol. 109, pp. 67–76, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. L. J. A. G. Ricker, A. Kijlstra, W. de Jager, A. T. A. Liem, F. Hendrikse, and E. C. la Heij, “Chemokine levels in subretinal fluid obtained during scleral buckling surgery after rhegmatogenous retinal detachment,” Investigative Ophthalmology & Visual Science, vol. 51, no. 8, pp. 4143–4150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. B. W. Whitcomb, E. F. Schisterman, M. A. Klebanoff et al., “Circulating chemokine levels and miscarriage,” American Journal of Epidemiology, vol. 166, no. 3, pp. 323–331, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. P. K. Baier, S. Eggstein, G. Wolff-Vorbeck, U. Baumgartner, and U. T. Hopt, “Chemokines in human colorectal carcinoma,” Anticancer Research, vol. 25, no. 5, pp. 3581–3584, 2005. View at Google Scholar · View at Scopus
  23. T. Kondo, F. Ito, H. Nakazawa, S. Horita, Y. Osaka, and H. Toma, “High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma,” The Journal of Urology, vol. 171, no. 6 I, pp. 2171–2175, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Ishikawa, S. Yoshida, S. Nakao et al., “Bone marrow-derived monocyte lineage cells recruited by MIP-1β promote physiological revascularization in mouse model of oxygen-induced retinopathy,” Laboratory Investigation, vol. 92, no. 1, pp. 91–101, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. G. K. Georgiou, M. Igglezou, I. Sainis et al., “Impact of breast cancer surgery on angiogenesis circulating biomarkers: a prospective longitudinal study,” World Journal of Surgical Oncology, vol. 11, article 213, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. E. L. Liclican, V. Nguyen, A. B. Sullivan, and K. Gronert, “Selective activation of the prostaglandin E2 circuit in chronic injury-induced pathologic angiogenesis,” Investigative Ophthalmology and Visual Science, vol. 51, no. 12, pp. 6311–6320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Mizutani, M. Ashikari, M. Tokoro, M. Nozaki, and Y. Ogura, “Suppression of laser-induced choroidal neovascularization by a CCR3 antagonist,” Investigative Ophthalmology & Visual Science, vol. 54, no. 2, pp. 1564–1572, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. R. Weihrauch, O. Manzke, M. Beyer et al., “Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor,” Cancer Research, vol. 65, no. 13, pp. 5516–5519, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. K. S. Reiners, A. Gossmann, E. P. Von Strandmann, B. Böll, A. Engert, and P. Borchmann, “Effects of the anti-VEGF Monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed hodgkin lymphoma,” Journal of Immunotherapy, vol. 32, no. 5, pp. 508–512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Buonamici, T. Trimarchi, M. G. Ruocco et al., “CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia,” Nature, vol. 459, no. 7249, pp. 1000–1004, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Comerford, Y. Harata-Lee, M. D. Bunting, C. Gregor, E. E. Kara, and S. R. McColl, “A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system,” Cytokine & Growth Factor Reviews, vol. 24, no. 3, pp. 269–283, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. Q. Zhang, L. Sun, L. Yin et al., “CCL19/CCR7 upregulates heparanase via specificity protein-1 (Sp1) to promote invasion of cell in lung cancer,” Tumor Biology, vol. 34, no. 5, pp. 2703–2708, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. S. R. Pickens, N. D. Chamberlain, M. V. Volin, R. M. Pope, A. M. Mandelin II, and S. Shahrara, “Characterization of CCL19 and CCL21 in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 63, no. 4, pp. 914–922, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Brühl, M. Mack, M. Niedermeier, D. Lochbaum, J. Schölmerich, and R. H. Straub, “Functional expression of the chemokine receptor CCR7 on fibroblast-like synoviocytes,” Rheumatology, vol. 47, no. 12, pp. 1771–1774, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Li, J. Wang, P. B. Wilson et al., “Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer,” International Journal of Cancer, vol. 79, pp. 455–459, 1998. View at Google Scholar
  36. L. R. Pasquale, M. E. Dorman-Pease, G. A. Lutty, H. A. Quigley, and H. D. Jampel, “Immunolocalization of TGF-β1, TGF-β2, and TGF-β3 in the anterior segment of the human eye,” Investigative Ophthalmology & Visual Science, vol. 34, no. 1, pp. 23–30, 1993. View at Google Scholar · View at Scopus
  37. G. A. Lutty, C. Merges, A. B. Threlkeld, S. Crone, and D. S. McLeod, “Heterogeneity in localization of isoforms of TGF-β in human retina, vitreous, and choroid,” Investigative Ophthalmology and Visual Science, vol. 34, no. 3, pp. 477–487, 1993. View at Google Scholar · View at Scopus
  38. H. Tanihara, M. Yoshida, M. Matsumoto, and N. Yoshimura, “Identification of transforming growth factor-β expressed in cultured human retinal pigment epithelial cells,” Investigative Ophthalmology & Visual Science, vol. 34, no. 2, pp. 413–419, 1993. View at Google Scholar · View at Scopus
  39. C. Li, R. Gardy, B. K. Seon et al., “Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis,” British Journal of Cancer, vol. 88, no. 9, pp. 1424–1431, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Zhou, S. Wang, and X. Xia, “Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy,” Current Eye Research, vol. 37, no. 5, pp. 416–420, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Semeraro, A. Cancarini, F. Morescalchi et al., “Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy,” Diabetes and Metabolism, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Costagliola, A. Daniele, R. dell'Omo et al., “Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection,” Experimental Eye Research, vol. 110, pp. 50–54, 2013. View at Publisher · View at Google Scholar · View at Scopus